SCHEMBL2916335

SCHEMBL2916335

O=C1O[C@@H](CCCCCOCc2ccccc2)[C@@H]1Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FASN P49327 1/20 0.61
CTRB1 P17538 1/20 0.55
PLA2G6 O60733 2/20 0.48
PLA2G4A P47712 1/20 0.48
F2 P00734 2/20 0.44
PRSS1 P07477 2/20 0.44
NAAA Q02083 3/20 0.43
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 1/20 0.40
DAGLA Q9Y4D2 2/20 0.40
EPHX2 P34913 1/20 0.39
KCNA3 P22001 1/20 0.37
KCNA5 P22460 1/20 0.37
TSHR P16473 1/20 0.37
GBA1 P04062 1/20 0.37
UGCG Q16739 1/20 0.37
GBA2 Q9HCG7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2916334 1.00 FASN (0.61) FASNCTRB1PLA2G6PLA2G4AF2
SCHEMBL2916331 1.00 FASN (0.61) FASNCTRB1PLA2G6PLA2G4AF2
SCHEMBL2916304 0.87 PLA2G6 (0.60) FASNPLA2G6PLA2G4ANAAADAGLA
SCHEMBL3448340 0.87 PLA2G6 (0.60) FASNPLA2G6PLA2G4ANAAADAGLA
SCHEMBL2916300 0.87 PLA2G6 (0.60) FASNPLA2G6PLA2G4ANAAADAGLA
SCHEMBL7631804 0.82 FASN (0.66) FASNCTRB1PLA2G6PLA2G4ADAGLA
SCHEMBL19514884 0.82 FASN (0.66) FASNCTRB1PLA2G6PLA2G4ADAGLA
SCHEMBL19514957 0.82 FASN (0.66) FASNCTRB1PLA2G6PLA2G4ADAGLA
SCHEMBL19514955 0.82 FASN (0.66) FASNCTRB1PLA2G6PLA2G4ADAGLA
SCHEMBL2916698 0.82 FASN (0.66) FASNCTRB1PLA2G6PLA2G4AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751126-B1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS ABBOTT PRODUCTS GMBH (DE) 2010-09-01 EP disclosed
EP-1751126-A1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS Solvay Pharmaceuticals GmbH (DE) 2007-02-14 EP disclosed
US-7074822-B2 Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2006-07-11 US disclosed
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-09-08 US disclosed
WO-2005080366-A1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them PNLIP, CEL, LIPE FASN 351/4885CTRB1 27/4885PLA2G6 193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.